0
Clinical Investigations: ASTHMA |

Clinically Important Improvements in Asthma-Specific Quality of Life, But No Difference in Conventional Clinical Indexes in Patients Changed From Conventional Beclomethasone Dipropionate to Approximately Half the Dose of Extrafine Beclomethasone Dipropionate*

Elizabeth F. Juniper, MB, MSc; David B. Price, MB BChir; Patti A. Stampone, MS; Jacques P. H. M. Creemers, MD; Stijn J. M. Mol, MD; Philip Fireman, MD
Author and Funding Information

Affiliations: *From the Department of Clinical Epidemiology and Biostatistics (Ms. Juniper), McMaster University, Hamilton, ON, Canada; the Department of General Practice and Primary Care (Mr. Price), University of Aberdeen, UK; 3M Pharmaceuticals (Ms. Stampone), St Paul, MN; the Department of Pulmonology (Dr. Creemers), Catharina Ziekenhuis, Eindhoven, the Netherlands; St. Joseph Ziekenhuis (Dr. Mol), Veldhoven, the Netherlands; and Children’s Hospital of Pittsburgh (Dr. Fireman), Pittsburgh, PA.,  A complete list of study participants is provided in the Appendix.

Correspondence to: Elizabeth F. Juniper, MCSP, MSc, 20 Marcuse Fields, Bosham, West Sussex, PO18 8NA, United Kingdom; e-mail: juniper@qoltech.co.uk



Chest. 2002;121(6):1824-1832. doi:10.1378/chest.121.6.1824
Text Size: A A A
Published online

Study objective: Clinical trials of asthma treatments usually use measures of asthma control to assess efficacy. However, it is also important to determine whether patients themselves benefit from interventions. The aim of this study was to evaluate health-related quality of life in patients with asthma switched from conventional chlorofluorocarbon (CFC) beclomethasone dipropionate (BDP) to hydrofluroalkane-134a (HFA) BDP extrafine aerosol at half the daily dose.

Design: Open-label, 12-month, parallel-group, randomized trial.

Setting: Fifty-seven centers in four countries (United States, Belgium, the Netherlands, and United Kingdom).

Patients: Four hundred seventy-three patients with a ≥ 6-month history of asthma, stable symptoms, and maintained on CFC-BDP, 400 to 1,600 μg/d.

Interventions: HFA-BDP, 200 to 800 μg/d (n = 354), or CFC-BDP, 400 to 1,600 μg/d (n = 119).

Measurements and results: The Asthma Quality of Life Questionnaire (AQLQ) and pulmonary function tests were completed at months 0, 2, 4, 8, and 12. For 1 month before each visit, patients made daily recordings of symptoms, peak expiratory flow, and β2-agonist use. Two hundred ninety-six patients completed the study (HFA-BDP, 83.6%; CFC-BDP, 83.2%). At month 12, improvements in overall AQLQ scores were greater in the HFA-BDP group than in the CFC-BDP group (p = 0.0024). The number of patients who need to be treated with HFA-BDP for one to have a clinically important improvement in overall asthma-specific quality of life compared with CFC-BDP was 7.3. There was no evidence of differences (p > 0.05) between treatment groups for airway caliber, symptoms, or β2-agonist use.

Conclusion: Clinically important improvements in the AQLQ score were observed at month 12 for HFA-BDP vs CFC-BDP, while conventional clinical indexes of pulmonary function and asthma control were similar in the two groups.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years.
National Institute for Health and Clinical Excellence (NICE) | 1/31/2008
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543